NCT07141407 Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
| NCT ID | NCT07141407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fred Hutchinson Cancer Center |
| Condition | Advanced Malignant Solid Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-04-08 |
| Primary Completion | 2026-10-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-04-08 with a primary completion date of 2026-10-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and their support person. Participation in ACP, which includes having end of life (EOL) care conversations and completing advance directives (e.g., living will, health care proxy, do not resuscitate order), improves quality EOL care. Despite this, less than half of patients with advanced cancer have EOL care conversations or complete advance directives. TAC coaching sessions are delivered by a social worker over the phone. They are designed to help patients and their support person communicate about ACP, manage the distress these conversations can cause, and participate in the process of ACP with a clear action plan of having goals-of-care conversations and completing advance directives. This may be an effective way to improve ACP participation in advanced cancer patients and their support person.
Eligibility Criteria
Inclusion Criteria: * PATIENT: Current diagnosis of stage III or IV cancer * PATIENT: Able to provide informed consent * PATIENT: Fluent in English or Spanish * PATIENT: Have access to a telephone, computer, or mobile device * CAREGIVER (SUPPORT PERSON): Person patient indicates provides support * CAREGIVER (SUPPORT PERSON): English or Spanish speaking * CAREGIVER (SUPPORT PERSON): 18 years of age or older * CAREGIVER (SUPPORT PERSON): Able to provide informed consent Exclusion Criteria: * PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer) * PATIENT: Receiving hospice at the time of enrollment * PATIENT: Younger than age 18
Contact & Investigator
Megan Shen, PhD
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT07141407 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Malignant Solid Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07141407 currently recruiting?
Yes, NCT07141407 is actively recruiting participants. Contact the research team at mshen2@fredhutch.org for enrollment information.
Where is the NCT07141407 trial being conducted?
This trial is being conducted at Everett, United States, Mount Vernon, United States, Seattle, United States.
Who is sponsoring the NCT07141407 clinical trial?
NCT07141407 is sponsored by Fred Hutchinson Cancer Center. The principal investigator is Megan Shen, PhD at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 80 participants.